Browse studies
Find your next paid study
148 recruiting studies matching your filters
Phase 1
IMetelstat and Azacitidine With or Without Venetoclax GIveN in rElapsed Acute Myeloid Leukemia (IMAGINE Trial)
IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patient…
Relapsed Acute Myeloid Leukemia
Estimated
~$10 – $7,500
Douglas TremblayNCT07320235
Phase 2
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed …
Relapsed CancerRefractory Multiple MyelomaMultiple Myeloma
Estimated
~$10 – $6,250
Massachusetts General HospitalNCT05922501
Phase 2
A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…
Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more
Estimated
~$10 – $7,500
Seda S. ToluNCT07283822
Phase 2
Phase 2, Single-Arm Trial of Comprehensive Ablative Bridging Irradiation (CABI) Prior to CD19 CAR-T Cell Therapy in High-Risk, Relapsed or Refractory Large B Cell Lymphoma in Patients With Bulky Disease
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therap…
Large B-cell LymphomaRelapsed Non-Hodgkin Lymphoma
Estimated
~$10 – $6,250
H. Lee Moffitt Cancer Center and Research InstituteNCT06104592